Brain-Targeted Intranasal Delivery of Protein-Based Gene Therapy for Treatment of Ischemic Stroke
January 2024
in “
Theranostics
”
Studysummary In this study involving a mouse model, researchers reported that intranasal delivery of protein-based CRISPR/dCas9 nanoparticles targeting the gene *Sirt1* reduced cerebral edema and increased survival following ischemic stroke, with no significant toxicity observed.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study presents a novel approach for treating ischemic stroke using a protein-based CRISPR/dCas9 system delivered intranasally. The system targets the neuroprotective gene <i>Sirt1</i> and is encapsulated in calcium phosphate nanoparticles to enhance stability and prevent degradation. These nanoparticles are conjugated with β-hydroxybutyrates to facilitate transfer into the brain via nasal epithelial cells. In a mouse model, this method effectively upregulated <i>Sirt1</i>, reduced cerebral edema, and increased survival rates after stroke, with no significant toxicity observed. The findings suggest that this delivery system could be a promising therapy for acute ischemic stroke.
